Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
1 Receptor
75%
Addiction
5%
Alcohol
8%
Brain Response
16%
Buprenorphine
16%
Cardiovascular Dysregulation
8%
Centers for Disease Control
5%
Cocaine
8%
Counseling
23%
Disease Prevention
5%
Drug Cues
16%
Drug Overdose Deaths
5%
Drug Response
16%
Drug-induced Reinstatement
13%
Extended-release Naltrexone
5%
Fentanyl
40%
GLP-1 Agonists
100%
Glucagon-like
75%
Heroin
12%
Heroin Seeking
15%
Heroin Self-administration
10%
Liraglutide
37%
Medications for Opioid Use Disorder
19%
Methadone
11%
Multicenter Clinical Trial
5%
Naltrexone
13%
Nicotine
8%
Non-opioid
9%
Obesity Treatment
9%
Opioid Relapse
5%
Opioid Use Disorder
100%
Opioids
11%
Patient Will
6%
Phase I Trial
8%
Placebo
5%
Placebo-controlled
5%
Polysomnography
6%
Randomized Double-blind
5%
Randomized Placebo-controlled Trial
5%
Receptor Agonist
54%
Relapse Rate
5%
Residential Treatment
13%
Respiratory Depression
8%
Reward Pathway
5%
Satiety
8%
Semaglutide
20%
Short-acting
5%
Sleep Problems
6%
Slow-wave Sleep
6%
Sodium
5%
Specific Aims
8%
Stress-induced
9%
Stress-induced Reinstatement
13%
Sweetwater
5%
Type 2 Diabetes Mellitus (T2DM)
12%
United States
8%
Pharmacology, Toxicology and Pharmaceutical Science
Buprenorphine
24%
Clinical Trial
24%
Diamorphine
45%
Diseases
100%
Drug Dependence
6%
Drug Overdose
12%
Duragesic
40%
Glucagon Like Peptide 1 Receptor Agonist
100%
Glucagon-Like Peptide 1 Receptor
29%
Liraglutide
49%
Maturity Onset Diabetes of the Young
12%
Methadone
19%
Naltrexone
23%
Nicotine
12%
Opiate Receptor
6%
Placebo
17%
Placebo-Controlled Study
6%
Rat
100%
Receptor
6%
Recurrence Risk
5%
Respiration Depression
8%
Semaglutide
22%
Sleep Disorder
13%
Sodium
5%
Syndrome
6%
Medicine and Dentistry
Addictive Behavior
5%
Arm
5%
Buprenorphine
16%
Buprenorphine Plus Naloxone
8%
Clinical Trial
16%
Diamorphine
36%
Diseases
16%
Drug Overdose
8%
Glucagon Like Peptide 1 Receptor
16%
Glucagon-Like Peptide-1 Agonist
60%
Ingestion
8%
Liraglutide
18%
Maturity Onset Diabetes of the Young
8%
Methadone
10%
Naltrexone
19%
Nicotine
8%
Opioid Abuse
60%
Outpatient
5%
Placebo
17%
Polysomnography
5%
Recurrence Risk
5%
Satiety
8%
Self-Administration
11%
Semaglutide
22%
Sleep Disorder
5%
Slow-Wave Sleep
5%